

Ruggero De Maria

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8260738/ruggero-de-maria-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

266
papers

24,412
citations

67
h-index

153
g-index

284
ext. papers

27,706
ext. citations

9.2
avg. IF

6.54
L-index

#	Paper	IF	Citations
266	PI3K-driven HER2 expression is a potential therapeutic target in colorectal cancer stem cells. <i>Gut</i> , 2022 , 71, 119-128	19.2	13
265	An organoid model of colorectal circulating tumor cells with stem cell features, hybrid EMT state and distinctive therapy response profile.. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022 , 41, 86	12.8	1
264	Mutational status of plasma exosomal KRAS predicts outcome in patients with metastatic colorectal cancer. <i>Scientific Reports</i> , 2021 , 11, 22686	4.9	1
263	The Targeting of MRE11 or RAD51 Sensitizes Colorectal Cancer Stem Cells to CHK1 Inhibition. <i>Cancers</i> , 2021 , 13,	6.6	4
262	Repeated Exposure to Subinfectious Doses of SARS-CoV-2 May Promote T Cell Immunity and Protection against Severe COVID-19. <i>Viruses</i> , 2021 , 13,	6.2	1
261	Diagnostic and prognostic potential of the proteomic profiling of serum-derived extracellular vesicles in prostate cancer. <i>Cell Death and Disease</i> , 2021 , 12, 636	9.8	7
260	CHK1 inhibitor sensitizes resistant colorectal cancer stem cells to nortoposentin. <i>IScience</i> , 2021 , 24, 1026641	6.4	14
259	Prospective Validation of the Italian Alliance Against Cancer Lung Panel in Patients With Advanced Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2021 , 22, e637-e641	4.9	1
258	The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial. <i>Scientific Reports</i> , 2021 , 11, 13770	4.9	0
257	Control of replication stress and mitosis in colorectal cancer stem cells through the interplay of PARP1, MRE11 and RAD51. <i>Cell Death and Differentiation</i> , 2021 , 28, 2060-2082	12.7	10
256	Therotyping cystic fibrosis in ALI culture and organoid models generated from patient-derived nasal epithelial conditionally reprogrammed stem cells. <i>European Respiratory Journal</i> , 2021 , 58,	13.6	6
255	Adipose stem cell niche reprograms the colorectal cancer stem cell metastatic machinery. <i>Nature Communications</i> , 2021 , 12, 5006	17.4	8
254	KEAP1 and TP53 Frame Genomic, Evolutionary, and Immunologic Subtypes of Lung Adenocarcinoma With Different Sensitivity to Immunotherapy. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 2065-2077	8.9	6
253	Nobiletin and Xanthohumol Sensitize Colorectal Cancer Stem Cells to Standard Chemotherapy. <i>Cancers</i> , 2021 , 13,	6.6	7
252	Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020 , 39, 279	12.8	12
251	A moonshot approach toward the management of cancer patients in the COVID-19 time: what have we learned and what could the Italian network of cancer centers (Alliance Against Cancer, ACC) do after the pandemic wave?. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020 , 39, 109	12.8	6
250	Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence. <i>Journal of Cellular Physiology</i> , 2020 , 235, 7900-7910	7	11

249	Low-intensity pulsed ultrasound affects growth, differentiation, migration, and epithelial-to-mesenchymal transition of colorectal cancer cells. <i>Journal of Cellular Physiology</i> , 2020 , 235, 5363-5377	7	5
248	CD147 Promotes Cell Small Extracellular Vesicles Release during Colon Cancer Stem Cells Differentiation and Triggers Cellular Changes in Recipient Cells. <i>Cancers</i> , 2020 , 12,	6.6	8
247	Multicohort and cross-platform validation of a prognostic Wnt signature in colorectal cancer. <i>Clinical and Translational Medicine</i> , 2020 , 10, e199	5.7	0
246	A pre-existing population of ZEB2 quiescent cells with stemness and mesenchymal features dictate chemoresistance in colorectal cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020 , 39, 2	12.8	29
245	Tuning Cancer Fate: Tumor Microenvironment Role in Cancer Stem Cell Quiescence and Reawakening. <i>Frontiers in Immunology</i> , 2020 , 11, 2166	8.4	19
244	Identification of Targets to Redirect CAR T Cells in Glioblastoma and Colorectal Cancer: An Arduous Venture. <i>Frontiers in Immunology</i> , 2020 , 11, 565631	8.4	13
243	Measuring Extracellular Vesicles by Conventional Flow Cytometry: Dream or Reality?. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	10
242	Targeting chemoresistant colorectal cancer via systemic administration of a BMP7 variant. <i>Oncogene</i> , 2020 , 39, 987-1003	9.2	17
241	Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting. <i>International Journal of Cancer</i> , 2020 , 146, 1917-1929	7.5	3
240	miR-1285-3p Controls Colorectal Cancer Proliferation and Escape from Apoptosis through DAPK2. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	5
239	A novel oral micellar fenretinide formulation with enhanced bioavailability and antitumour activity against multiple tumours from cancer stem cells. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019 , 38, 373	12.8	16
238	Zika virus infection induces MiR34c expression in glioblastoma stem cells: new perspectives for brain tumor treatments. <i>Cell Death and Disease</i> , 2019 , 10, 263	9.8	16
237	Cancer-associated fibroblasts as abettors of tumor progression at the crossroads of EMT and therapy resistance. <i>Molecular Cancer</i> , 2019 , 18, 70	42.1	190
236	PTEN Tumor-Suppressor: The Dam of Stemness in Cancer. <i>Cancers</i> , 2019 , 11,	6.6	61
235	A new bioavailable fenretinide formulation with antiproliferative, antimetabolic, and cytotoxic effects on solid tumors. <i>Cell Death and Disease</i> , 2019 , 10, 529	9.8	23
234	Mutations in the KEAP1-NFE2L2 Pathway Define a Molecular Subset of Rapidly Progressing Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 1924-1934	8.9	33
233	Organoids as a new model for improving regenerative medicine and cancer personalized therapy in renal diseases. <i>Cell Death and Disease</i> , 2019 , 10, 201	9.8	61
232	A multicenter REtrospective observational study of first-line treatment with PERTuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study. <i>Cancer Biology and Therapy</i> , 2019 , 20, 192-200	4.6	17

231	Two-Step Co-Immunoprecipitation (TIP). <i>Current Protocols in Molecular Biology</i> , 2019 , 125, e80	2.9	1
230	Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience. <i>Journal of Cellular Physiology</i> , 2019 , 234, 7708-7717	7	16
229	The clinical significance of PD-L1 in advanced gastric cancer is dependent on mutations and ATM expression. <i>Oncolmmunology</i> , 2018 , 7, e1457602	7.2	6
228	Conditionally reprogrammed cells (CRC) methodology does not allow the in vitro expansion of patient-derived primary and metastatic lung cancer cells. <i>International Journal of Cancer</i> , 2018 , 143, 88-99 ⁵	7.5	15
227	miR-663 sustains NSCLC by inhibiting mitochondrial outer membrane permeabilization (MOMP) through PUMA/BBC3 and BTG2. <i>Cell Death and Disease</i> , 2018 , 9, 49	9.8	18
226	Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. <i>Cell Death and Differentiation</i> , 2018 , 25, 486-541	12.7	2160
225	HSP90 inhibition alters the chemotherapy-driven rearrangement of the oncogenic secretome. <i>Oncogene</i> , 2018 , 37, 1369-1385	9.2	13
224	The Hippo pathway in normal development and cancer. <i>Pharmacology & Therapeutics</i> , 2018 , 186, 60-72	13.9	85
223	CHK1-targeted therapy to deplete DNA replication-stressed, p53-deficient, hyperdiploid colorectal cancer stem cells. <i>Gut</i> , 2018 , 67, 903-917	19.2	45
222	GLUT 1 receptor expression and circulating levels of fasting glucose in high grade serous ovarian cancer. <i>Journal of Cellular Physiology</i> , 2018 , 233, 1396-1401	7	9
221	How to Assess Drug Resistance in Cancer Stem Cells. <i>Methods in Molecular Biology</i> , 2018 , 1692, 107-115	1.4	3
220	Replication stress response in cancer stem cells as a target for chemotherapy. <i>Seminars in Cancer Biology</i> , 2018 , 53, 31-41	12.7	23
219	Micro-Economics of Apoptosis in Cancer: ncRNAs Modulation of BCL-2 Family Members. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	15
218	Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018 , 37, 140	12.8	22
217	Deep sequencing and pathway-focused analysis revealed multigene oncodriver signatures predicting survival outcomes in advanced colorectal cancer. <i>Oncogenesis</i> , 2018 , 7, 55	6.6	6
216	Expression of the Hippo transducer TAZ in association with WNT pathway mutations impacts survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy. <i>Journal of Translational Medicine</i> , 2018 , 16, 22	8.5	10
215	Two-Step Coimmunoprecipitation (TIP) Enables Efficient and Highly Selective Isolation of Native Protein Complexes. <i>Molecular and Cellular Proteomics</i> , 2018 , 17, 993-1009	7.6	5
214	Precision Trial Drawer, a Computational Tool to Assist Planning of Genomics-Driven Trials in Oncology.. <i>JCO Precision Oncology</i> , 2018 , 2, 1-16	3.6	1

213	Coexisting YAP expression and TP53 missense mutations delineates a molecular scenario unexpectedly associated with better survival outcomes in advanced gastric cancer. <i>Journal of Translational Medicine</i> , 2018 , 16, 247	8.5	5
212	Renal cancer: new models and approach for personalizing therapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018 , 37, 217	12.8	9
211	PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer. <i>Scientific Reports</i> , 2017 , 7, 43013	4.9	36
210	DNA damage repair and survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy. <i>International Journal of Cancer</i> , 2017 , 140, 2587-2595	7.5	21
209	Body mass index modifies the relationship between γ H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer. <i>BMC Cancer</i> , 2017 , 17, 101	4.8	11
208	C-Met/miR-130b axis as novel mechanism and biomarker for castration resistance state acquisition. <i>Oncogene</i> , 2017 , 36, 3718-3728	9.2	31
207	Type-I-interferons in infection and cancer: Unanticipated dynamics with therapeutic implications. <i>Oncolmmunology</i> , 2017 , 6, e1314424	7.2	69
206	DNA Damage in Stem Cells. <i>Molecular Cell</i> , 2017 , 66, 306-319	17.6	172
205	Cancer stem cells: at the forefront of personalized medicine and immunotherapy. <i>Current Opinion in Pharmacology</i> , 2017 , 35, 1-11	5.1	37
204	The clinical value of patient-derived glioblastoma tumorspheres in predicting treatment response. <i>Neuro-Oncology</i> , 2017 , 19, 1097-1108	1	37
203	Integrin $\alpha 5$ Is a Functional Marker and Potential Therapeutic Target in Glioblastoma. <i>Cell Stem Cell</i> , 2017 , 21, 35-50.e9	18	66
202	Differentiation Affects the Release of Exosomes from Colon Cancer Cells and Their Ability to Modulate the Behavior of Recipient Cells. <i>American Journal of Pathology</i> , 2017 , 187, 1633-1647	5.8	34
201	Noncanonical GLI1 signaling promotes stemness features and in vivo growth in lung adenocarcinoma. <i>Oncogene</i> , 2017 , 36, 4641-4652	9.2	58
200	Expression of phosphorylated Hippo pathway kinases (MST1/2 and LATS1/2) in HER2-positive and triple-negative breast cancer patients treated with neoadjuvant therapy. <i>Cancer Biology and Therapy</i> , 2017 , 18, 339-346	4.6	13
199	Association between AXL, Hippo Transducers, and Survival Outcomes in Male Breast Cancer. <i>Journal of Cellular Physiology</i> , 2017 , 232, 2246-2252	7	9
198	Analysis of the ATR-Chk1 and ATM-Chk2 pathways in male breast cancer revealed the prognostic significance of ATR expression. <i>Scientific Reports</i> , 2017 , 7, 8078	4.9	13
197	Blocking endothelin-1-receptor/ β -catenin circuit sensitizes to chemotherapy in colorectal cancer. <i>Cell Death and Differentiation</i> , 2017 , 24, 1811-1820	12.7	25
196	Dual targeting of HER3 and MEK may overcome HER3-dependent drug-resistance of colon cancers. <i>Oncotarget</i> , 2017 , 8, 108463-108479	3.3	7

195	Protein drug target activation homogeneity in the face of intra-tumor heterogeneity: implications for precision medicine. <i>Oncotarget</i> , 2017 , 8, 48534-48544	3.3	5
194	A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience. <i>Oncotarget</i> , 2017 , 8, 56921-56931	3.3	41
193	Establishment of patient-derived renal cell carcinoma (RCC) models based on orthotopic xenografts (PDX) and cancer stem cell (CSC) isolation to provide prognostic and predictive information.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e16055-e16055	2.2	
192	A microRNA code for prostate cancer metastasis. <i>Oncogene</i> , 2016 , 35, 1180-92	9.2	92
191	hMENA(11a) contributes to HER3-mediated resistance to PI3K inhibitors in HER2-overexpressing breast cancer cells. <i>Oncogene</i> , 2016 , 35, 887-96	9.2	9
190	Normal vs cancer thyroid stem cells: the road to transformation. <i>Oncogene</i> , 2016 , 35, 805-15	9.2	16
189	Presurgical window of opportunity trial design as a platform for testing anticancer drugs: Pros, cons and a focus on breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 106, 132-42	7	7
188	Cancer Stem Cell-Based Models of Colorectal Cancer Reveal Molecular Determinants of Therapy Resistance. <i>Stem Cells Translational Medicine</i> , 2016 , 5, 511-23	6.9	35
187	Metabolic/Proteomic Signature Defines Two Glioblastoma Subtypes With Different Clinical Outcome. <i>Scientific Reports</i> , 2016 , 6, 21557	4.9	54
186	HMG-CoAR expression in male breast cancer: relationship with hormone receptors, Hippo transducers and survival outcomes. <i>Scientific Reports</i> , 2016 , 6, 35121	4.9	5
185	Topographic expression of the Hippo transducers TAZ and YAP in triple-negative breast cancer treated with neoadjuvant chemotherapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2016 , 35, 62	12.8	19
184	Epithelial-mesenchymal transition: a new target in anticancer drug discovery. <i>Nature Reviews Drug Discovery</i> , 2016 , 15, 311-25	64.1	216
183	Hippo pathway and breast cancer stem cells. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 99, 115-22	7	34
182	DNA Damage and Repair Biomarkers in Cervical Cancer Patients Treated with Neoadjuvant Chemotherapy: An Exploratory Analysis. <i>PLoS ONE</i> , 2016 , 11, e0149872	3.7	8
181	Histone acetyltransferase inhibitor CPTH6 preferentially targets lung cancer stem-like cells. <i>Oncotarget</i> , 2016 , 7, 11332-48	3.3	36
180	"Triple positive" early breast cancer: an observational multicenter retrospective analysis of outcome. <i>Oncotarget</i> , 2016 , 7, 17932-44	3.3	26
179	The Hippo transducers TAZ/YAP and their target CTGF in male breast cancer. <i>Oncotarget</i> , 2016 , 7, 43188-43198	3.3	26
178	Translational impact of patient-derived glioblastoma tumorspheres.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2025-2025	2.2	

177	Analysis of the hippo transducers TAZ and YAP in cervical cancer and its microenvironment. <i>Oncolmmunology</i> , 2016 , 5, e1160187	7.2	24
176	Numb Expression Contributes to the Maintenance of an Undifferentiated State in Human Epidermis. <i>Cell Transplantation</i> , 2016 , 25, 353-64	4	6
175	miR-15/miR-16 loss, miR-21 upregulation, or deregulation of their target genes predicts poor prognosis in prostate cancer patients. <i>Molecular and Cellular Oncology</i> , 2016 , 3, e1109744	1.2	10
174	Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies. <i>Expert Review of Vaccines</i> , 2016 , 15, 1327-36	5.2	58
173	Cancer stem cells as a potential therapeutic target in thyroid carcinoma. <i>Oncology Letters</i> , 2016 , 12, 2254-2260	1.9	19
172	Aloe-emodin exerts a potent anticancer and immunomodulatory activity on BRAF-mutated human melanoma cells. <i>European Journal of Pharmacology</i> , 2015 , 762, 283-92	5.3	32
171	Efficacy of chemotherapy in metastatic male breast cancer patients: a retrospective study. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015 , 34, 26	12.8	13
170	Dynamic regulation of the cancer stem cell compartment by Cripto-1 in colorectal cancer. <i>Cell Death and Differentiation</i> , 2015 , 22, 1700-13	12.7	36
169	Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer. <i>Cell Death and Disease</i> , 2015 , 6, e1850	9.8	31
168	Androgen receptor and antiandrogen therapy in male breast cancer. <i>Cancer Letters</i> , 2015 , 368, 20-25	9.9	15
167	TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells. <i>Oncogene</i> , 2015 , 34, 681-90	9.2	222
166	Cancer stem cells: perspectives for therapeutic targeting. <i>Cancer Immunology, Immunotherapy</i> , 2015 , 64, 91-7	7.4	55
165	Essential versus accessory aspects of cell death: recommendations of the NCCD 2015. <i>Cell Death and Differentiation</i> , 2015 , 22, 58-73	12.7	643
164	The Hippo transducers TAZ and YAP in breast cancer: oncogenic activities and clinical implications. <i>Expert Reviews in Molecular Medicine</i> , 2015 , 17, e14	6.7	55
163	Alliance Against Cancer, the network of Italian cancer centers bridging research and care. <i>Journal of Translational Medicine</i> , 2015 , 13, 360	8.5	8
162	Role of autophagy in the maintenance and function of cancer stem cells. <i>International Journal of Developmental Biology</i> , 2015 , 59, 95-108	1.9	30
161	Alleanza Contro il Cancro: the accreditation system of the Excellence Network of Italian Cancer Centers in the precision medicine era. <i>Tumori</i> , 2015 , 101 Suppl 1, S64-6	1.7	3
160	A BMP7 Variant Inhibits Tumor Angiogenesis In Vitro and In Vivo through Direct Modulation of Endothelial Cell Biology. <i>PLoS ONE</i> , 2015 , 10, e0125697	3.7	10

159	The Regina Elena National Cancer Institute process of accreditation according to the standards of the Organisation of European Cancer Institutes. <i>Tumori</i> , 2015 , 101 Suppl 1, S51-4	1.7	1
158	International Accreditation of Cancer Centres of Italian Network of Alleanza contro il Cancro: introductory remarks. <i>Tumori</i> , 2015 , 101 Suppl 1, 1	1.7	
157	Role of gonadotropin-releasing hormone analogues in metastatic male breast cancer: results from a pooled analysis. <i>Journal of Hematology and Oncology</i> , 2015 , 8, 53	22.4	30
156	(1) H NMR spectroscopy of glioblastoma stem-like cells identifies alpha-aminoadipate as a marker of tumor aggressiveness. <i>NMR in Biomedicine</i> , 2015 , 28, 317-26	4.4	16
155	A predictive signature for therapy assignment and risk assessment in prostate cancer. <i>Oncoscience</i> , 2015 , 2, 920-3	0.8	5
154	Anti-tumoral effect of desmethylclomipramine in lung cancer stem cells. <i>Oncotarget</i> , 2015 , 6, 16926-38	3.3	18
153	miR-135b suppresses tumorigenesis in glioblastoma stem-like cells impairing proliferation, migration and self-renewal. <i>Oncotarget</i> , 2015 , 6, 37241-56	3.3	36
152	Predictive significance of DNA damage and repair biomarkers in triple-negative breast cancer patients treated with neoadjuvant chemotherapy: An exploratory analysis. <i>Oncotarget</i> , 2015 , 6, 42773-80	3.3	13
151	CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis. <i>Cell Stem Cell</i> , 2014 , 14, 342-56	18	499
150	¹ H NMR detects different metabolic profiles in glioblastoma stem-like cells. <i>NMR in Biomedicine</i> , 2014 , 27, 129-45	4.4	19
149	Antitumor effect of miR-197 targeting in p53 wild-type lung cancer. <i>Cell Death and Differentiation</i> , 2014 , 21, 774-82	12.7	70
148	Antiandrogen therapy in metastatic male breast cancer: results from an updated analysis in an expanded case series. <i>Breast Cancer Research and Treatment</i> , 2014 , 148, 73-80	4.4	22
147	Elimination of quiescent/slow-proliferating cancer stem cells by Bcl-XL inhibition in non-small cell lung cancer. <i>Cell Death and Differentiation</i> , 2014 , 21, 1877-88	12.7	67
146	Aromatase inhibitors for metastatic male breast cancer: molecular, endocrine, and clinical considerations. <i>Breast Cancer Research and Treatment</i> , 2014 , 147, 227-35	4.4	16
145	Dual promoter usage as regulatory mechanism of let-7c expression in leukemic and solid tumors. <i>Molecular Cancer Research</i> , 2014 , 12, 878-89	6.6	14
144	Cancer stem cells: are they responsible for treatment failure?. <i>Future Oncology</i> , 2014 , 10, 2033-44	3.6	12
143	Histone deacetylase inhibition synergistically enhances pemetrexed cytotoxicity through induction of apoptosis and autophagy in non-small cell lung cancer. <i>Molecular Cancer</i> , 2014 , 13, 230	42.1	47
142	Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo. <i>Cell Death and Disease</i> , 2014 , 5, e1223	9.8	44

141	MicroRNA as new tools for prostate cancer risk assessment and therapeutic intervention: results from clinical data set and patients samples. <i>BioMed Research International</i> , 2014 , 2014, 146170	3	40
140	Colorectal cancer stem cells: from the crypt to the clinic. <i>Cell Stem Cell</i> , 2014 , 15, 692-705	18	265
139	The Hippo transducer TAZ as a biomarker of pathological complete response in HER2-positive breast cancer patients treated with trastuzumab-based neoadjuvant therapy. <i>Oncotarget</i> , 2014 , 5, 9619-25	3.3	30
138	Approaching the increasing complexity of non-small cell lung cancer taxonomy. <i>Current Pharmaceutical Design</i> , 2014 , 20, 3973-81	3.3	2
137	Analysis of the combined action of miR-143 and miR-145 on oncogenic pathways in colorectal cancer cells reveals a coordinate program of gene repression. <i>Oncogene</i> , 2013 , 32, 4806-13	9.2	140
136	Type-3 metabotropic glutamate receptors regulate chemoresistance in glioma stem cells, and their levels are inversely related to survival in patients with malignant gliomas. <i>Cell Death and Differentiation</i> , 2013 , 20, 396-407	12.7	49
135	Advances towards the design and development of personalized non-small-cell lung cancer drug therapy. <i>Expert Opinion on Drug Discovery</i> , 2013 , 8, 1381-97	6.2	6
134	BTG2 loss and miR-21 upregulation contribute to prostate cell transformation by inducing luminal markers expression and epithelial-mesenchymal transition. <i>Oncogene</i> , 2013 , 32, 1843-53	9.2	85
133	Targeting apoptosis pathways in cancer stem cells. <i>Cancer Letters</i> , 2013 , 332, 374-82	9.9	86
132	Presence of anaplastic lymphoma kinase in inflammatory breast cancer. <i>SpringerPlus</i> , 2013 , 2, 497		36
131	Mek inhibition results in marked antitumor activity against metastatic melanoma patient-derived melanospheres and in melanosphere-generated xenografts. <i>Journal of Experimental and Clinical Cancer Research</i> , 2013 , 32, 91	12.8	15
130	Erythropoietin activates cell survival pathways in breast cancer stem-like cells to protect them from chemotherapy. <i>Cancer Research</i> , 2013 , 73, 6393-400	10.1	31
129	Chemotherapy of skull base chordoma tailored on responsiveness of patient-derived tumor cells to rapamycin. <i>Neoplasia</i> , 2013 , 15, 773-82	6.4	14
128	Checkpoint kinase 1 inhibitors for potentiating systemic anticancer therapy. <i>Cancer Treatment Reviews</i> , 2013 , 39, 525-33	14.4	47
127	Epigenetic silencing of Id4 identifies a glioblastoma subgroup with a better prognosis as a consequence of an inhibition of angiogenesis. <i>Cancer</i> , 2013 , 119, 1004-12	6.4	36
126	AMPK inhibition enhances apoptosis in MLL-rearranged pediatric B-acute lymphoblastic leukemia cells. <i>Leukemia</i> , 2013 , 27, 1019-27	10.7	35
125	Protein pathway activation mapping of colorectal metastatic progression reveals metastasis-specific network alterations. <i>Clinical and Experimental Metastasis</i> , 2013 , 30, 309-16	4.7	20
124	Biological and clinical implications of cancer stem cells in primary brain tumors. <i>Frontiers in Oncology</i> , 2013 , 3, 6	5.3	10

123	Systems analysis of the NCI-60 cancer cell lines by alignment of protein pathway activation modules with "-OMIC" data fields and therapeutic response signatures. <i>Molecular Cancer Research</i> , 2013 , 11, 676-85	6.6	30
122	Sphere-forming cell subsets with cancer stem cell properties in human musculoskeletal sarcomas. <i>International Journal of Oncology</i> , 2013 , 43, 95-102	4.4	33
121	Gene expression analysis of PTEN positive glioblastoma stem cells identifies DUB3 and Wee1 modulation in a cell differentiation model. <i>PLoS ONE</i> , 2013 , 8, e81432	3.7	8
120	Functional role of microRNAs in prostate cancer and therapeutic opportunities. <i>Critical Reviews in Oncogenesis</i> , 2013 , 18, 303-15	1.3	5
119	Accreditation for excellence of cancer research institutes: recommendations from the Italian Network of Comprehensive Cancer Centers. <i>Tumori</i> , 2013 , 99, 293e-8e	1.7	3
118	Increased phospho-mTOR expression in megakaryocytic cells derived from CD34+ progenitors of essential thrombocythaemia and myelofibrosis patients. <i>British Journal of Haematology</i> , 2012 , 159, 237-40	4.5	12
117	A BMP7 variant inhibits the tumorigenic potential of glioblastoma stem-like cells. <i>Cell Death and Differentiation</i> , 2012 , 19, 1644-54	12.7	49
116	Cancer stem cell definitions and terminology: the devil is in the details. <i>Nature Reviews Cancer</i> , 2012 , 12, 767-75	31.3	489
115	Benzodeazaflavins as sirtuin inhibitors with antiproliferative properties in cancer stem cells. <i>Journal of Medicinal Chemistry</i> , 2012 , 55, 8193-7	8.3	27
114	Proliferation state and polo-like kinase1 dependence of tumorigenic colon cancer cells. <i>Stem Cells</i> , 2012 , 30, 1819-30	5.8	39
113	Discovery of salermide-related sirtuin inhibitors: binding mode studies and antiproliferative effects in cancer cells including cancer stem cells. <i>Journal of Medicinal Chemistry</i> , 2012 , 55, 10937-47	8.3	70
112	Disulfiram, an old drug with new potential therapeutic uses for human hematological malignancies. <i>International Journal of Cancer</i> , 2012 , 131, 2197-203	7.5	58
111	The transient receptor potential vanilloid-2 cation channel impairs glioblastoma stem-like cell proliferation and promotes differentiation. <i>International Journal of Cancer</i> , 2012 , 131, E1067-77	7.5	54
110	DNA damage repair pathways in cancer stem cells. <i>Molecular Cancer Therapeutics</i> , 2012 , 11, 1627-36	6.1	113
109	The mitogen-activated protein kinase (MAPK) cascade controls phosphatase and tensin homolog (PTEN) expression through multiple mechanisms. <i>Journal of Molecular Medicine</i> , 2012 , 90, 667-79	5.5	46
108	MicroRNAs and prostate cancer: from preclinical research to translational oncology. <i>Cancer Journal (Sudbury, Mass)</i> , 2012 , 18, 253-61	2.2	32
107	Knockdown of ubiquitin ligases in glioblastoma cancer stem cells leads to cell death and differentiation. <i>Journal of Biomolecular Screening</i> , 2012 , 17, 152-62		9
106	Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy. <i>Cell Death and Differentiation</i> , 2012 , 19, 768-78	12.7	140

105	EGFR inhibition abrogates leiomyosarcoma cell chemoresistance through inactivation of survival pathways and impairment of CSC potential. <i>PLoS ONE</i> , 2012 , 7, e46891	3.7	27
104	Bone morphogenetic protein 4 induces differentiation of colorectal cancer stem cells and increases their response to chemotherapy in mice. <i>Gastroenterology</i> , 2011 , 140, 297-309	13.3	173
103	Expression of EGFRvIII in glioblastoma: prognostic significance revisited. <i>Neoplasia</i> , 2011 , 13, 1113-21	6.4	90
102	Not so lonely at the top for cancer stem cells. <i>Cell Stem Cell</i> , 2011 , 9, 289-90	18	10
101	Control of tumor and microenvironment cross-talk by miR-15a and miR-16 in prostate cancer. <i>Oncogene</i> , 2011 , 30, 4231-42	9.2	201
100	The Notch2-Jagged1 interaction mediates stem cell factor signaling in erythropoiesis. <i>Cell Death and Differentiation</i> , 2011 , 18, 371-80	12.7	19
99	Pro-inflammatory gene expression in solid glioblastoma microenvironment and in hypoxic stem cells from human glioblastoma. <i>Journal of Neuroinflammation</i> , 2011 , 8, 32	10.1	81
98	Expression of the stem cell marker CD133 in recurrent glioblastoma and its value for prognosis. <i>Cancer</i> , 2011 , 117, 162-74	6.4	67
97	NF- κ B localization in multiple myeloma plasma cells and mesenchymal cells. <i>Leukemia Research</i> , 2011 , 35, 52-60	2.7	14
96	Cancer stem cells and chemosensitivity. <i>Clinical Cancer Research</i> , 2011 , 17, 4942-7	12.9	150
95	Prevention of chemotherapy-induced anemia and thrombocytopenia by constant administration of stem cell factor. <i>Clinical Cancer Research</i> , 2011 , 17, 6185-91	12.9	19
94	Therapeutic targeting of cancer stem cells. <i>Frontiers in Oncology</i> , 2011 , 1, 10	5.3	19
93	Cancer Stem Cells 2011 , 151-168		
92	Translating basic research in cancer patient care. <i>Annali Dell'Istituto Superiore Di Sanita</i> , 2011 , 47, 64-71	1.6	3
91	Lung cancer stem cells: tools and targets to fight lung cancer. <i>Oncogene</i> , 2010 , 29, 4625-35	9.2	112
90	Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. <i>Nature</i> , 2010 , 468, 824-8	50.4	1023
89	Functional protein network activation mapping reveals new potential molecular drug targets for poor prognosis pediatric BCP-ALL. <i>PLoS ONE</i> , 2010 , 5, e13552	3.7	38
88	TRPV2 channel negatively controls glioma cell proliferation and resistance to Fas-induced apoptosis in ERK-dependent manner. <i>Carcinogenesis</i> , 2010 , 31, 794-803	4.6	76

87	Knockdown of cancer testis antigens modulates neural stem cell marker expression in glioblastoma tumor stem cells. <i>Journal of Biomolecular Screening</i> , 2010 , 15, 830-9		9
86	Tumorigenic and metastatic activity of human thyroid cancer stem cells. <i>Cancer Research</i> , 2010 , 70, 8874-851		177
85	Obesity hormone leptin induces growth and interferes with the cytotoxic effects of 5-fluorouracil in colorectal tumor stem cells. <i>Endocrine-Related Cancer</i> , 2010 , 17, 823-33	5.7	46
84	Thymosin beta4 targeting impairs tumorigenic activity of colon cancer stem cells. <i>FASEB Journal</i> , 2010 , 24, 4291-301	0.9	31
83	Transferrin receptor 2 is frequently and highly expressed in glioblastomas. <i>Translational Oncology</i> , 2010 , 3, 123-34	4.9	80
82	MicroRNAs and prostate cancer. <i>Endocrine-Related Cancer</i> , 2010 , 17, F1-17	5.7	117
81	New models for cancer research: human cancer stem cell xenografts. <i>Current Opinion in Pharmacology</i> , 2010 , 10, 380-4	5.1	41
80	Downregulation of thymosin beta4 in neural progenitor grafts promotes spinal cord regeneration. <i>Journal of Cell Science</i> , 2009 , 122, 4195-207	5.3	24
79	Suppressor of cytokine signaling 3 sensitizes anaplastic thyroid cancer to standard chemotherapy. <i>Cancer Research</i> , 2009 , 69, 6141-8	10.1	30
78	Colon cancer stem cells. <i>Journal of Molecular Medicine</i> , 2009 , 87, 1097-104	5.5	161
77	Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes. <i>Cell Death and Differentiation</i> , 2009 , 16, 1093-107	12.7	533
76	THE MIR-15A/MIR-16-1 CLUSTER CONTROLS PROSTATE CANCER PROGRESSION CONTROL BY TARGETING OF MULTIPLE ONCOGENIC ACTIVITIES. <i>Journal of Urology</i> , 2009 , 181, 188-188	2.5	2
75	Activity of the BH3 mimetic ABT-737 on polycythemia vera erythroid precursor cells. <i>Blood</i> , 2009 , 113, 1522-5	2.2	16
74	Roscovitine sensitizes breast cancer cells to TRAIL-induced apoptosis through a pleiotropic mechanism. <i>Cell Research</i> , 2008 , 18, 664-76	24.7	30
73	Mesenchymal differentiation of glioblastoma stem cells. <i>Cell Death and Differentiation</i> , 2008 , 15, 1491-8	12.7	87
72	Loss of pericentromeric DNA methylation pattern in human glioblastoma is associated with altered DNA methyltransferases expression and involves the stem cell compartment. <i>Oncogene</i> , 2008 , 27, 358-63	9.2	65
71	The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. <i>Nature Medicine</i> , 2008 , 14, 1271-7	50.5	820
70	Identification and expansion of the tumorigenic lung cancer stem cell population. <i>Cell Death and Differentiation</i> , 2008 , 15, 504-14	12.7	1333

69	Paclitaxel loading in PLGA nanospheres affected the in vitro drug cell accumulation and antiproliferative activity. <i>BMC Cancer</i> , 2008 , 8, 212	4.8	26
68	The secretion and maturation of prosaposin and procathepsin D are blocked in embryonic neural progenitor cells. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2008 , 1783, 1480-9	4.9	9
67	Type-3 metabotropic glutamate receptors negatively modulate bone morphogenetic protein receptor signaling and support the tumourigenic potential of glioma-initiating cells. <i>Neuropharmacology</i> , 2008 , 55, 568-76	5.5	38
66	Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme. <i>Clinical Cancer Research</i> , 2008 , 14, 8205-12	12.9	288
65	Antitumor activity of bortezomib alone and in combination with TRAIL in human acute myeloid leukemia. <i>Acta Haematologica</i> , 2008 , 120, 19-30	2.7	24
64	Blocking the APRIL circuit enhances acute myeloid leukemia cell chemosensitivity. <i>Haematologica</i> , 2008 , 93, 1899-902	6.6	5
63	The inhibition of the highly expressed miR-221 and miR-222 impairs the growth of prostate carcinoma xenografts in mice. <i>PLoS ONE</i> , 2008 , 3, e4029	3.7	187
62	Apoptosis in normal and cancer stem cells. <i>Critical Reviews in Oncology/Hematology</i> , 2008 , 66, 42-51	7	69
61	Quantum dots for biomedical applications. <i>Expert Opinion on Medical Diagnostics</i> , 2008 , 2, 315-22		5
60	Colon cancer stem cells. <i>Gut</i> , 2008 , 57, 538-48	19.2	53
59	Human neural progenitor cells display limited cytotoxicity and increased oligodendrogenesis during inflammation. <i>Cell Death and Differentiation</i> , 2007 , 14, 876-8	12.7	15
58	Identification and expansion of human colon-cancer-initiating cells. <i>Nature</i> , 2007 , 445, 111-5	50.4	3310
57	MUC1 oncoprotein promotes refractoriness to chemotherapy in thyroid cancer cells. <i>Cancer Research</i> , 2007 , 67, 5522-30	10.1	27
56	Chemotherapy-induced thrombocytopenia derives from the selective death of megakaryocyte progenitors and can be rescued by stem cell factor. <i>Cancer Research</i> , 2007 , 67, 4767-73	10.1	65
55	Proteasome inhibitors synergize with tumor necrosis factor-related apoptosis-induced ligand to induce anaplastic thyroid carcinoma cell death. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007 , 92, 1938-42	5.6	47
54	Antitumor Activity of Bortezomib Alone and in Combination with TRAIL in Human Acute Myeloid Leukemia.. <i>Blood</i> , 2007 , 110, 4307-4307	2.2	
53	Influence of local environment on the differentiation of neural stem cells engrafted onto the injured spinal cord. <i>Neurological Research</i> , 2006 , 28, 488-92	2.7	37
52	Establishing tumor cell lines from aggressive telomerase-positive chordomas of the skull base. Technical note. <i>Journal of Neurosurgery</i> , 2006 , 105, 482-4	3.2	15

51	Autocrine production of interleukin-4 and interleukin-10 is required for survival and growth of thyroid cancer cells. <i>Cancer Research</i> , 2006 , 66, 1491-9	10.1	99
50	Increased death receptor resistance and FLIPshort expression in polycythemia vera erythroid precursor cells. <i>Blood</i> , 2006 , 107, 3495-502	2.2	43
49	Enforced expression of KDR receptor promotes proliferation, survival and megakaryocytic differentiation of TF1 progenitor cell line. <i>Cell Death and Differentiation</i> , 2006 , 13, 61-74	12.7	23
48	Chemotherapy resistance of glioblastoma stem cells. <i>Cell Death and Differentiation</i> , 2006 , 13, 1238-41	12.7	497
47	The PU.1 transcription factor induces cyclin D2 expression in U937 cells. <i>Leukemia</i> , 2006 , 20, 2208-10	10.7	3
46	Inhibition of DNA methylation sensitizes glioblastoma for tumor necrosis factor-related apoptosis-inducing ligand-mediated destruction. <i>Cancer Research</i> , 2005 , 65, 11469-77	10.1	75
45	Endogenous activation of metabotropic glutamate receptors supports the proliferation and survival of neural progenitor cells. <i>Cell Death and Differentiation</i> , 2005 , 12, 1124-33	12.7	113
44	NF-kappaB protects Behçet's disease T cells against CD95-induced apoptosis up-regulating antiapoptotic proteins. <i>Arthritis and Rheumatism</i> , 2005 , 52, 2179-91		47
43	Multiple members of the TNF superfamily contribute to IFN-gamma-mediated inhibition of erythropoiesis. <i>Journal of Immunology</i> , 2005 , 175, 1464-72	5.3	74
42	Absence of caspase 8 and high expression of PED protect primitive neural cells from cell death. <i>Journal of Experimental Medicine</i> , 2004 , 200, 1257-66	16.6	91
41	IL-4 protects tumor cells from anti-CD95 and chemotherapeutic agents via up-regulation of antiapoptotic proteins. <i>Journal of Immunology</i> , 2004 , 172, 5467-77	5.3	125
40	CD95 death-inducing signaling complex formation and internalization occur in lipid rafts of type I and type II cells. <i>European Journal of Immunology</i> , 2004 , 34, 1930-40	6.1	87
39	Activation of Fas receptor is required for the increased formation of the disialoganglioside GD3 in cultured cerebellar granule cells committed to apoptotic death. <i>Neuroscience</i> , 2004 , 126, 889-98	3.9	19
38	Potential role of APRIL as autocrine growth factor for megakaryocytopoiesis. <i>Blood</i> , 2004 , 104, 3169-72	2.2	24
37	Involvement of interferon regulatory factor-1 in monocyte CD95 expression and CD95-mediated apoptosis. <i>Cell Death and Differentiation</i> , 2003 , 10, 615-7	12.7	7
36	Control of erythroid cell production via caspase-mediated cleavage of transcription factor SCL/Tal-1. <i>Cell Death and Differentiation</i> , 2003 , 10, 905-13	12.7	42
35	Stem cell factor protects erythroid precursor cells from chemotherapeutic agents via up-regulation of BCL-2 family proteins. <i>Blood</i> , 2003 , 102, 87-93	2.2	44
34	Thyroid cancer resistance to chemotherapeutic drugs via autocrine production of interleukin-4 and interleukin-10. <i>Cancer Research</i> , 2003 , 63, 6784-90	10.1	89

33	Autoimmune thyroid disease: new models of cell death in autoimmunity. <i>Nature Reviews Immunology</i> , 2002 , 2, 195-204	36.5	192
32	Beta-amyloid-induced synthesis of the ganglioside GD3 is a requisite for cell cycle reactivation and apoptosis in neurons. <i>Journal of Neuroscience</i> , 2002 , 22, 3963-8	6.6	80
31	Fas-FasL in Hashimoto's thyroiditis. <i>Journal of Clinical Immunology</i> , 2001 , 21, 19-23	5.7	25
30	Response to Thyrocytes - not innocent bystanders in autoimmune disease <i>Nature Immunology</i> , 2001 , 2, 183	19.1	2
29	Response to TH1 and TH2 cytokine control of thyrocyte survival in thyroid autoimmunity <i>Nature Immunology</i> , 2001 , 2, 371-371	19.1	1
28	Control of target cell survival in thyroid autoimmunity by T helper cytokines via regulation of apoptotic proteins. <i>Nature Immunology</i> , 2000 , 1, 483-8	19.1	121
27	CD95/CD95L interactions and their role in autoimmunity. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2000 , 5, 419-24	5.4	13
26	Negative regulation of erythropoiesis by caspase-mediated cleavage of GATA-1. <i>Nature</i> , 1999 , 401, 489-93	30.4	327
25	Caspase activation without death. <i>Cell Death and Differentiation</i> , 1999 , 6, 1075-80	12.7	97
24	KDR receptor: a key marker defining hematopoietic stem cells. <i>Science</i> , 1999 , 285, 1553-8	33.3	418
23	Lipid and glycolipid mediators in CD95-induced apoptotic signaling. <i>Results and Problems in Cell Differentiation</i> , 1999 , 23, 65-76	1.4	3
22	Fas-FasL interactions: a common pathogenetic mechanism in organ-specific autoimmunity. <i>Trends in Immunology</i> , 1998 , 19, 121-125		18
21	Acidic sphingomyelinase (ASM) is necessary for fas-induced GD3 ganglioside accumulation and efficient apoptosis of lymphoid cells. <i>Journal of Experimental Medicine</i> , 1998 , 187, 897-902	16.6	151
20	Fas-FasL interactions: a common pathogenetic mechanism in organ-specific autoimmunity. <i>Trends in Immunology</i> , 1998 , 19, 121-5		97
19	Nitric oxide primes pancreatic beta cells for Fas-mediated destruction in insulin-dependent diabetes mellitus. <i>Journal of Experimental Medicine</i> , 1997 , 186, 1193-200	16.6	223
18	Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis. <i>Science</i> , 1997 , 275, 960-3	33.3	508
17	Requirement for GD3 ganglioside in CD95- and ceramide-induced apoptosis. <i>Science</i> , 1997 , 277, 1652-5	33.3	376
16	Defective expression of CD95 (FAS/APO-1) molecule suggests apoptosis impairment of T and B cells in HLA-B8, DR3-positive individuals. <i>Human Immunology</i> , 1997 , 55, 39-45	2.3	19

15	Fas-induced changes in cdc2 and cdk2 kinase activity are not sufficient for triggering apoptosis in HUT-78 cells. <i>Journal of Cellular Biochemistry</i> , 1997 , 64, 579-585	4.7	13
14	Ceramide inhibits antigen uptake and presentation by dendritic cells. <i>Journal of Experimental Medicine</i> , 1996 , 184, 2411-6	16.6	90
13	Functional expression of Fas and Fas ligand on human gut lamina propria T lymphocytes. A potential role for the acidic sphingomyelinase pathway in normal immunoregulation. <i>Journal of Clinical Investigation</i> , 1996 , 97, 316-22	15.9	104
12	Stimulated human lamina propria T cells manifest enhanced Fas-mediated apoptosis. <i>Journal of Clinical Investigation</i> , 1996 , 98, 2616-22	15.9	112
11	Low bcl-2 expression and increased spontaneous apoptosis in T-lymphocytes from newly-diagnosed IDDM patients. <i>Diabetologia</i> , 1995 , 38, 953-8	10.3	20
10	Defective expression of the apoptosis-inducing CD95 (Fas/APO-1) molecule on T and B cells in IDDM. <i>Diabetologia</i> , 1995 , 38, 1449-54	10.3	29
9	T-cell activation in HLA-B8, DR3-positive individuals. Early antigen expression defect in vitro. <i>Human Immunology</i> , 1995 , 42, 289-94	2.3	31
8	Epstein-Barr virus DNA is present both in CD10/CD77 positive and negative subsets of human tonsillar lymphocytes. <i>Cancer Letters</i> , 1995 , 89, 125-8	9.9	2
7	Apoptotic signaling through CD95 (Fas/Apo-1) activates an acidic sphingomyelinase. <i>Journal of Experimental Medicine</i> , 1994 , 180, 1547-52	16.6	494
6	Triggering of human monocyte activation through CD69, a member of the natural killer cell gene complex family of signal transducing receptors. <i>Journal of Experimental Medicine</i> , 1994 , 180, 1999-2004	16.6	138
5	Defective T cell receptor/CD3 complex signaling in human type I diabetes. <i>European Journal of Immunology</i> , 1994 , 24, 999-1002	6.1	42
4	The CD69 receptor: a multipurpose cell-surface trigger for hematopoietic cells. <i>Trends in Immunology</i> , 1994 , 15, 479-83		373
3	Continuous in vivo activation and transient hyporesponsiveness to TcR/CD3 triggering of human gut lamina propria lymphocytes. <i>European Journal of Immunology</i> , 1993 , 23, 3104-8	6.1	69
2	Study of T-cell activation in type I diabetic patients and pre-type I diabetic subjects by cytometric analysis: antigen expression defect in vitro. <i>Journal of Clinical Immunology</i> , 1993 , 13, 68-78	5.7	24
1	Analysis of T-lymphocyte subsets after phytohemagglutinin stimulation in normal and type 1 diabetic mothers and their infants. <i>American Journal of Reproductive Immunology</i> , 1992 , 28, 65-70	3.8	7